The clinicopathological significance of Lgr5 expression in lung adenocarcinoma

Lung Cancer

Volumn 82, Issue 1, 2013, Pages 143-148

  Ryuge, Shinichiro ^a   Sato, Yuichi ^a   Jiang, Shi Xu ^a   Wang, Guoqin ^b   Kobayashi, Makoto ^a   Nagashio, Ryo ^a   Katono, Ken ^a   Iyoda, Akira ^a   Satoh, Yukitoshi ^a   Masuda, Noriyuki ^a  

^a KITASATO UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer stem cell; Immunohistochemistry; Lgr5; Lung adenocarcinoma; NSCLC; Prognostic marker

Indexed keywords

ANTINEOPLASTIC AGENT; LGR5 PROTEIN; PROTEIN; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR CDX2; UNCLASSIFIED DRUG;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CYTOPLASM; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG ALVEOLUS EPITHELIUM; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR INVASION;

CANCER STEM CELL; CSC; EPIREGULIN; EREG; HAZARD RATIO; HR; IMMUNOHISTOCHEMISTRY; LEUCINE-RICH REPEAT-CONTAINING G-PROTEIN-COUPLED RECEPTOR 5; LGR5; LUNG ADENOCARCINOMA; NON-SMALL CELL LUNG CANCER; NSCLC; P-TNM; PATHOLOGICAL TNM; PROGNOSTIC MARKER; TERMINAL RESPIRATORY UNIT; TRU;

ADENOCARCINOMA; AGED; DNA-BINDING PROTEINS; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, G-PROTEIN-COUPLED; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84884419449     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.06.010     Document Type: Article

References (33)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66.
2. Kitamura H., Okudela K., Yazawa T., Sato H., Shimoyamada H. Cancer stem cell: implications in cancer biology and therapy with special reference to lung cancer. Lung Cancer 2009, 66:275-281.
3. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008, 8:755-768.
4. Toyooka S., Mitsudomi T., Soh J., Aokage K., Yamane M., Oto T., et al. Molecular oncology of lung cancer. Gen Thorac Cardiovasc Surg 2011, 59:527-537.
5. Jiang F., Qiu Q., Khanna A., Todd N.W., Deepak J., Xing L., et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 2009, 7:330-338.
6. Li F., Zeng H., Ying K. The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas. Med Oncol 2011, 28:1458-1462.
7. Li X., Wan L., Geng J., Wu C.L., Bai X. Aldehyde dehydrogenase 1A1 possesses stem-like properties and predicts lung cancer patient outcome. J Thorac Oncol 2012, 7:1235-1245.
8. Shien K., Toyooka S., Ichimura K., Soh J., Furukawa M., Maki Y., et al. Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy. Lung Cancer 2012, 77:162-167.
9. Woo T., Okudela K., Mitsui H., Yazawa T., Ogawa N., Tajiri M., et al. Prognostic value of CD133 expression in stage I lung adenocarcinomas. Int J Clin Exp Pathol 2010, 4:32-42.
10. Zhang X.Y., Dong Q.G., Huang J.S., Huang A.M., Shi C.L., Jin B., et al. The expression of stem cell-related indicators as a prognostic factor in human lung adenocarcinoma. J Surg Oncol 2010, 102:856-862.
11. Ryuge S., Sato Y., Wang G.Q., Matsumoto T., Jiang S.X., Katono K., et al. Prognostic significance of nestin expression in resected non-small cell lung cancer. Chest 2011, 139:862-869.
12. Barker N., van Es J.H., Kuipers J., Kujala P., van den Born M., Cozijnsen M., et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007, 449:1003-1007.
13. Jaks V., Barker N., Kasper M., van Es J.H., Snippert H.J., Clevers H., et al. Lgr5 marks cycling, yet long-lived, hair follicle stem cells. Nat Genet 2008, 40:1291-1299.
14. van der Flier L.G., Clevers H. Stem cells, self-renewal, and differentiation in the intestinal epithelium. Annu Rev Physiol 2009, 71:241-260.
15. Barker N., Ridgway R.A., van Es J.H., van de Wetering M., Begthel H., van den Born M., et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009, 457:608-611.
16. Merlos-Suarez A., Barriga F.M., Jung P., Iglesias M., Cespedes M.V., Rossell D., et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 2011, 8:511-524.
17. Uchida H., Yamazaki K., Fukuma M., Yamada T., Hayashida T., Hasegawa H., et al. Overexpression of leucine-rich repeat-containing G protein-coupled receptor 5 in colorectal cancer. Cancer Sci 2010, 101:1731-1737.
18. Travis W.D., Coby T.V., Corrin B., Shimosato E.Y. World Health Organization International histological classification of tumors; histological typing of lung and pleural tumors 1999, Springer, Berlin.
19. Goldstraw P., Crowley J., Chansky K., Giroux D.J., Groome P.A., Rami-Porta R., et al. Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007, 2:706-714.
20. Inamura K., Satoh Y., Okumura S., Nakagawa K., Tsuchiya E., Fukayama M., et al. Pulmonary adenocarcinomas with enteric differentiation: histologic and immunohistochemical characteristics compared with metastatic colorectal cancers and usual pulmonary adenocarcinomas. Am J Surg Pathol 2005, 29:660-665.
21. Rubin D.B. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997, 127:757-763.
22. Tanaka H., Yanagisawa K., Shinjo K., Taguchi A., Maeno K., Tomida S., et al. Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res 2007, 67:6007-6011.
23. Yuasa Y. Control of gut differentiation and intestinal-type gastric carcinogenesis. Nat Rev Cancer 2003, 3:592-600.
24. Werling R.W., Yaziji H., Bacchi C.E., Gown A.M. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol 2003, 27:303-310.
25. Becker L., Huang Q., Mashimo H. Lgr5, an intestinal stem cell marker, is abnormally expressed in Barrett's esophagus and esophageal adenocarcinoma. Dis Esophagus 2010, 23:168-174.
26. Nakata S., Campos B., Bageritz J., Lorenzo Bermejo J., Becker N., Engel F., et al. LGR5 is a marker of poor prognosis in glioblastoma and is required for survival of brain cancer stem-like cells. Brain Pathol 2012, 23:60-72.
27. Saigusa S., Inoue Y., Tanaka K., Toiyama Y., Kawamura M., Okugawa Y., et al. Significant correlation between LKB1 and LGR5 gene expression and the association with poor recurrence-free survival in rectal cancer after preoperative chemoradiotherapy. J Cancer Res Clin Oncol 2012, 139:131-138.
28. Takahashi H., Ishii H., Nishida N., Takemasa I., Mizushima T., Ikeda M., et al. Significance of Lgr5(+ve) cancer stem cells in the colon and rectum. Ann Surg Oncol 2011, 18:1166-1174.
29. Schuijers J., Clevers H. Adult mammalian stem cells: the role of Wnt, Lgr5 and R-spondins. EMBO J 2012, 31:2685-2696.
30. Sunaga N., Kohno T., Kolligs F.T., Fearon E.R., Saito R., Yokota J. Constitutive activation of the Wnt signaling pathway by CTNNB1 (beta-catenin) mutations in a subset of human lung adenocarcinoma. Genes Chromosomes Cancer 2001, 30:316-321.
31. Winn R.A., Bremnes R.M., Bemis L., Franklin W.A., Miller Y.E., Cool C., et al. gamma-Catenin expression is reduced or absent in a subset of human lung cancers and re-expression inhibits transformed cell growth. Oncogene 2002, 21:7497-7506.
32. Kobayashi S., Yamada-Okabe H., Suzuki M., Natori O., Kato A., Matsubara K., et al. LGR5-positive colon cancer stem cells interconvert with drug-resistant LGR5-negative cells and are capable of tumor reconstitution. Stem Cells 2012, 30:2631-2644.
33. Sunaga N., Kaira K., Imai H., Shimizu K., Nakano T., Shames D.S., et al. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer. Oncogene 2012, [Epub ahead of print].